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Abstract
Background: Olfactory dysfunction is a prevalent problem with a significant impact
on quality of life and increased mortality. Limited effective therapies exist. Platelet-
rich plasma (PRP) is an autologous biologic product with anti-inflammatory and neu-
roprotective effects. This novel pilot study evaluated the role of PRP on olfactory
neuroregeneration in patients with hyposmia.
Methods: Seven patients who had olfactory loss greater than 6 months in duration,
no evidence of sinonasal inflammatory disease, and no improvement with olfactory
training and budesonide topical rinses were enrolled in this preliminary study.
Patients received a single intranasal injection of PRP into the mucosa of the olfactory
cleft. The Sniffin' Sticks olfactory test consisting of threshold, discrimination, and
identification measurements (TDI) was administered at the beginning of the study
and at 1 and 3 months.
Results: All patients reported a subjective improvement of their smell shortly after
injection but then stabilized. At 3-month post-treatment, two patients with func-
tional anosmia (TDI < 16) did not improve significantly. Five patients with hyposmia
(TDI > 16 but <30) showed an improvement with 60% achieving normosmia
(TDI > 30) at 3-month follow-up. On average, patients with baseline TDI > 16
improved by 5.85 points with the most significant improvement in the threshold
subcomponent. There were no adverse outcomes from intranasal PRP injections.
Conclusion: PRP appears safe for use in the treatment of olfactory loss, and prelimi-
nary data suggest possible efficacy, especially for those with moderate yet persistent
loss. Further studies will help determine optimal frequency and duration of use.
Level of evidence: 2B
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1 | INTRODUCTION
Olfactory dysfunction is a prevalent disorder that affects up to 20%
of the general population and has significant effects on a person's
quality of life as well as increased morbidity and mortality.1-3 The eti-
ology of olfactory dysfunction is quite varied, including postviral,
post-traumatic, and idiopathic loss of smell. Unfortunately, with these
etiologies, the likelihood of spontaneous recovery is generally poor,
with only approximately one-third of people regaining function and
the duration of loss negatively correlating with recovery rate.4,5 Treat-
ment for olfactory dysfunction is also limited. Best evidence studies
recommend olfactory training and topical steroid nasal irrigations as
potential therapeutics, yet both have limited efficacy.6-9
Promisingly, the olfactory neuroepithelium and olfactory filae,
peripheral nerve fibers that traverse the cribriform plate into the nasal
cavity, have the ability to regenerate and thus may serve as potential
therapeutic targets for patients with olfactory dysfunction. Platelet-
rich plasma (PRP) is an autologous biologic product derived from fresh
whole blood containing a high concentration of platelets. PRP is
known to have anti-inflammatory and pro-regenerative properties
including upregulation of growth factors including transforming
growth factor, vascular endothelial growth factor, epidermal growth
factor, and insulin-like growth factor.10 It has been used as a safe ther-
apy, effective in treating inflammation, wound healing, and peripheral
neuropathies in other clinical settings.11-13 In particular, PRP has been
shown to promote axon regeneration and neuroregeneration.14-17
The role of PRP on olfactory neuroregeneration and related
inflammation is unknown, but a preliminary animal study showed
potential functional benefits of topical PRP in an anosmia induced
mouse model.18 One pilot study evaluated PRP for hyposmia in
humans and reported subjective improvements in five patients follow-
ing treatment.19 However, that study lacked quantitative measure-
ments of olfaction pre- and post-treatment and other standardized
norms. Herein, we aimed to investigate the safety and role of PRP in
patients with persistent olfactory loss as measured by validated olfac-
tory testing. This represents a novel use of PRP to promote olfactory
neuroregeneration and stimulate growth in an attempt to recover
olfaction and taste.
2 | METHODS
This was a single-arm pilot study evaluating patients with smell loss
for over 6 months but under 12 months. Informed consent and
approval from the Stanford Institutional Review Board Committee
were obtained.
2.1 | Patient selection
Inclusion criteria included adult patients (>18 years of age) with quan-
titative olfactory dysfunction documented by a University of Pen-
nsylvania's Smell Identification Test (UPSIT) score ≤33 during their
initial visit to Stanford Sinus Center. Patients must have trialed both
olfactory training and budesonide nasal irrigations for at least
3 months and had radiographic imaging that demonstrated normal
paranasal anatomy and olfactory bulb. Exclusion criteria included a
history of inflammatory sinonasal disease, prior sinonasal surgery,
<6 months or >12 months of smell loss, or history of any bleeding dis-
orders or use of blood thinner medications.
2.2 | Procedure
Recruited patients partook in additional baseline olfactory testing
using the validated Sniffin' Sticks to determine their odor threshold,
discrimination, and identification scores (TDI) with each subscore
ranging from 0 to 16 with a total 48 possible points.20 In our study,
the threshold scores were scored from 0 to 16 rather than 1 to
16, with T = 0 representing those who fail to recognize the most
intensely odorant pen (No. 1) and T = 1 representing those who only
recognize pen No. 1. This scoring modification was recommended by
prior studies and allowed us to distinguish between patients who ini-
tially had an inability to distinguish the most concentrated odorant
pen and those who could recognize this concentration.21
Following olfactory testing, patients underwent a one-time submu-
cosal intranasal injection of 1 mL PRP in each olfactory cleft, under
endoscopic visualization, first along the superior septum just posterior
to the head of themiddle turbinate and then againmore posteriorly into
the septum across from the leading edge of the superior turbinate, to
cover the entire region of the olfactory epithelium along the septum as
shown in Figure 1. The isolation of PRP was carried out as dictated by
the GS30-PURE II Protocol A (Emcyte, Ft Myers, Florida). This protocol
isolates PRP products with high platelet, low granulocyte count, and
F IGURE 1 Endoscopic view of the right olfactory epithelium with
the sites of PRP injection depicted by the two asterisks. A 1-mL PRP
was injected on each side of the nasal cavity and was split into two
injections, first along the superior septum just posterior to the head of
the middle turbinate and then again about 1 cm posteriorly into the
septum across from the leading edge of the superior turbinate
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minimal red blood cells. Briefly, 20 mL of patient's whole blood was
drawn and added to 5 mL of sodium citrate (SC) anticoagulant. The
blood was centrifuged at 4200 rpm for 1 minute upon which the plate-
let plasma suspension supernatant was aspirated and re-centrifuged at
4200 rpm for 5 minutes. The subsequent supernatant or the platelet
poor plasma was discarded until 2 mL of PRP remained. The PRP was
drawn up into two separate 1-mL syringes and injected intranasally
with a 27-g needle into the mucosa of the olfactory cleft that had been
topically anesthetized with pledget application of 4% lidocaine and
0.1% phenylephrine. Patients were observed for 15 minutes
postprocedure for any adverse effects and subsequently discharged.
Patients returned to clinic for a subsequent Sniffin' Sticks olfaction test-
ing at 1-month and 3-month intervals post-treatment. Postprocedural
nasal endoscopy was also performed to evaluate the health of the nasal
mucosa.
2.3 | Statistical analysis
A student's paired two-tailed t test was utilized to compare overall
TDI scores in our patients.
3 | RESULTS
Seven female, nonsmoking patients with ages between 32 and
66 years were enrolled in this study (Table 1). Patients had smell loss
duration from 6 to 11 months due to nonsinonasal disease’-related
etiologies. These included postviral, post-traumatic, and post-
anesthetic exposure causes of olfactory loss. All patients had under-
gone multiple therapies including olfactory training and budesonide
nasal irrigations for at least 3 months without improvement in their
sense of smell.
Following PRP injection, all patients reported a subjective
improvement of their smell at their one-month follow-up visit
(Table 2). Patients reported the ability to distinguish specific scents
including rosemary, varnish, and soaps that were not previously
detected. At 3-month follow-up, none of the patients reported a con-
tinued improvement in their sense of smell beyond the first month
but felt improved compared to pretreatment baseline.
For a majority of patients, there was continued improvement in their
olfaction following PRP therapy up to 3 months post-treatment. Overall,
therewas a significant improvement in average TDI values at the 3-month
follow-up compared to baseline (23.6 vs 19.5, P = .026, Figure 2). Two
patients had baseline functional anosmia (TDI score <16), suggestive of an
inability to perceive any common or useful odors in daily life.22 For these
patients (Patient 1 and 2), therewasminimum to no improvement in olfac-
tion scores at 3 months despitemild increases in their TDI at 1-month and
initial positive assessments. The remaining five other patients with base-
line hyposmia (TDI > 16 but <30) but not anosmia showed continued
improvement in olfaction at 3 months. Three patients achieved nor-
mosmia (TDI > 30) at 3-month follow-up. On average, the five hyposmic
patients improved their overall TDI score by 5.85 points.
A 5.5 point improvement in TDI score was previously determined
to be the minimal clinically important difference (MCID) for olfactory
improvement with a clinically notable improvement after a 2.5-point
increase in the threshold subscore and a 3.0-point increase in the dis-
crimination and identification subscores.23 Two patients achieved
MCID in total TDI score at 3-month follow-up while two other
patients achieved normosmia but had TDI improvements of 5 and 4.5
points (Table 2). At 1-month follow-up, most patients showed greatest
improvement in their ability to discriminate odors with four of the
seven patients achieving MCID in the discrimination subscore. How-
ever, by 3-month postprocedure, most patients showed the greatest
improvement in the threshold subcomponent.
In this study, there were no adverse outcomes from intranasal
PRP injections. Follow-up nasal endoscopy showed no evidence of
intranasal synechiae, inflammation, or mucosal disturbances at the
olfactory cleft bilaterally. No patient reported a significant decrease in
their sense of smell during any period following PRP therapy.
TABLE 1 Patient demographics
Subject Gender
Age
(years) Etiology of loss
Duration of loss
(months) Baseline UPSIT Smoker Prior therapeutics
1 F 66 postviral 11 17/40 anosmia N Topical steroid irrigations, olfactory
training
2 F 58 postviral 11 9/40 anosmia N Topical steroid irrigations, olfactory
training, oral steroids, acupuncture
3 F 57 postviral 6 27/40 moderate
microsmia
N Topical steroid irrigations, olfactory training,
oral steroids
4 F 56 postviral 9 28/40 moderate
microsmia
N Topical steroid irrigations, olfactory training,
oral steroids
5 F 44 postviral 10 18/40 anosmia N Topical steroid irrigations, olfactory training,
oral steroids
6 F 45 post-traumatic 6 12/40 anosmia N Topical steroid irrigations, olfactory training
7 F 32 postanesthetic exposure 6 9/40 anosmia N Topical steroid irrigations, olfactory training
Abbreviation: UPSIT: University of Pennsylvania Smell Identification Test.
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4 | DISCUSSION
This is a pilot study evaluating the role of PRP in neuro-olfactory
regeneration in the setting of hyposmia and is the first to demonstrate
improvement in smell using validated olfactory measurements follow-
ing PRP therapy. Importantly, there were no adverse outcomes fol-
lowing intranasal PRP injections. Patients reported no intranasal
symptoms or decreases in sense of smell. Keeping in mind that there
have been reports of visual loss from intranasal steroid injections, all
linked to the large particles that are present within a steroid emulsion,
we took care to ensure that the PRP was prepared and immediately
used to decrease any opportunity for particle formation, even though
the material itself is not in emulsion form at all and mixed with an anti-
coagulant, and thus risk is already exceptionally low for embolization.
Standard injection precautions were taken to ensure no injection
intravascularly and patients are awake during the procedure and
TABLE 2 Change in olfaction based on TDI scores at 1 and 3 months following treatment with PRP
Abbreviations: Δ, change in score from baseline;T, threshold; D, discrimination; I, identification.
aAchieved minimally clinically important difference (Δ5.5 total for TDI changes, subcategory: Δ2.5 for threshold, Δ3.0 for discrimination and identification).
F IGURE 2 Total TDI scores at baseline, 1 and 3 months post-
PRP. Among the entire group, mean TDI scores increased from
19.5 at baseline to 23.6 points at 3 months, statistically significant
at P = .026
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would be able to report any visual changes immediately during the
injection.
Thus far, there are few options for patients with olfactory loss par-
ticularly those unrelated to sinonasal inflammation. These patients had
at least 6 months of olfactory loss as well as failed prior treatments with
olfactory training and budesonide nasal irrigations, the only two vali-
dated treatments for nonsinonasal olfactory dysfunction with level 1 evi-
dence. A failure to improve after 6 months as well as using these two
therapies suggested that there was a lower likelihood of spontaneous
recovery. After 12 months, we know peripheral nerve regeneration is
unlikely.24 Thus, for the purposes of this initial study, we excluded
patients with a greater 12-month history of olfactory loss.
Following PRP therapy, three patients achieved normosmia at
their 3-month follow-up and two patients achieved the MCID with a
TDI increase of over six points. However, all patients subjectively con-
tinued to report smell loss. In light of recent findings suggesting spon-
taneous recovery is possible even after a year,4,25 we should consider
our results in that context. However, the direct temporal relationship
of the improvement in our patients after injection causes us to con-
sider this a finding worth investigating further.
In this study, interestingly, although five patients had a baseline
UPSIT score that fell into the anosmia category (<19/40), only two
patients were characterized as functional anosmics based on their
Sniffin' sticks test. At baseline, these patients reported no or negligible
sense of smell in everyday life. Both patients demonstrated little
improvement in olfactory function compared to others in the study
despite initial increases in scent discrimination at 1-month
postprocedure. This suggests that PRP therapy may be more benefi-
cial in those with a mild to moderate loss and the potential for olfac-
tory neuroregeneration may require a certain level of pre-existing
neural activity. It is important to also note that these two patients also
were the two oldest patients in our sample size and their duration of
loss was nearly 12 months, both factors known to be negative predic-
tors in smell recovery. It is also interesting that in spite of lack of
major quantitative improvement, these two patients had a similar sub-
jective feeling of improvement following injection that all participants
acknowledged. This may be due to the placebo effect of the treat-
ment or suggest that an individual's everyday smell loss experience
has nuances that cannot be completely captured by our olfactory test
battery.
In this study, all the patients who were enrolled were coinciden-
tally female. This is not surprising, as females tend to dominate the
smell loss patient population. This is perhaps related to the greater
subjective loss they may feel as a group, although population studies
have shown that females tend to have higher baseline olfaction scores
compared to male.22,26,27 Most patients suffered from a postviral
smell loss etiology. However, one patient had a post-traumatic loss,
and one from a postanesthetic smell loss. Postanesthetic smell loss,
although exceedingly rare, has been reported in the literature and can
be permanent with a direct temporal relationship following general
anesthesia.28 This etiology has been seen multiple times in our own
smell loss center related to anesthesia for surgeries for areas far away
from the head and neck region.
It is worth noting that our PRP protocol utilized a low concentra-
tion of SC as an anticoagulant for the purification of PRP. Compared
to other anticoagulants, SC has been found to have high platelet
recovery and mesenchymal stromal cell proliferation which makes it
an optimal anticoagulant.29 However, there are studies that have
suggested SC can improve olfactory dysfunction in postinfectious
loss.30 In this particular study, a difference was seen when SC is used
as a direct topical therapy but only for short term. In our protocol, SC
is diluted to a final concentration of approximately 16%. Furthermore,
studies by the PRP manufacturer have shown a 3- to 5-fold increase
in growth factor production with PRP + SC compared to SC alone
(data unpublished, Emcyte, Ft Myers, Florida).
All patients subjectively noted an improvement in their smell
immediately following PRP injections with enhanced detection of cer-
tain specific odors. However, this subjective improvement did not
continue despite evidence of improved olfaction scores at their
3-month follow-up. In our pilot study, only a single PRP injection was
performed to first assess the safety and feasibility of this therapy.
Mavrogeni and colleagues described four PRP injections with 4-week
intervals in between without any safety concerns.19 Taking this
together with our findings from this study, future studies may benefit
from multiple PRP treatments.
Given its novelty and invasive experimental design, there is no
standardized or optimal dosage or concentration recommended for
PRP injections and commercial preparation techniques are varied. We
injected 1 mL PRP in this pilot study as an appropriate amount that
can be introduced into the olfactory cleft that can fill the entire region
of the olfactory epithelium submucosal space without too much back
pressure and leakage. Our technique relied on a double-step centri-
fuge process to obtain enrichment of platelets that was up to five
times baseline platelet concentration according to the manufacturer's
brochure (Emcyte, Ft Myers, Florida). Prior studies using this same
protocol as our study demonstrated an average yield with a 3.5-fold
increase in platelets concentration compared to whole blood.31 The
concentration and volume of PRP injected may have a significant
impact on olfaction recovery. A previous in vitro study showed that
an intermediate PRP concentration was optimal in proliferation of
Schwann cells for peripheral nerve regeneration.16 These studies sug-
gest that PRP activity is modulated in a dose-dependent mode and
further investigation is needed to determine the optimal concentra-
tion of PRP in its therapy for olfactory outcomes.
As a single-arm pilot study involving a small number of patients, a
weakness is the lack of randomization and placebo arm, bringing the
potential question of whether our results were simply spontaneous
recovery. We recognize a control group would be optimal to assess
true efficacy and rule out placebo effect. However, with a novel ther-
apy and particularly one that has a procedural component involving a
peripheral blood draw and intranasal injection, we felt strongly that a
pilot single-arm study with a small number of patients was more
appropriate to establish safety, tolerability, and begin the investigation
toward possible efficacy. Now that safety and tolerability have been
established, we do plan on incorporating a placebo control in our
upcoming randomized controlled trial.
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Additionally, our exclusion criteria of patients who demonstrated
persistent loss for 6 months and had not already trialed other proven
therapies such as olfactory training do suggest that spontaneous
recovery is not the main factor in our results. Additionally, our finding
that the hyposmia group improved while the anosmia group did not
follows the same paradigm that all neurologic injury follows with
regard to severity and prognosis, with or without intervention.
This is the first study to use quantitative olfactory measures to dem-
onstrate a potential improvement of smell with PRP intranasal injections.
A small sample size was used as part of this pilot study and the findings
should be interpreted with caution. There was a statistically significant
improvement in the average TDI at P = .026. However, given the small
number of patients in this study, statistical analysis is difficult to interpret,
and this study was not powered to detect a difference.
5 | CONCLUSION
PRP appears safe for use in the treatment of olfactory loss. In this
study, we have preliminary data that suggests possible efficacy, espe-
cially for those with moderate yet persistent loss of smell. Further
studies will help determine optimal frequency and duration of use.
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